Literature DB >> 3780140

Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.

A J Taggart, C Astbury, J S Dixon, H A Bird.   

Abstract

The pharmacokinetic profile of a single 10 mg oral dose of prednisolone was studied in three groups of six patients with rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and bronchial asthma (BA) who were already receiving steroid therapy. A fourth group of age and sex-matched normal controls was also studied. Kinetic parameters (including elimination half-life, area under the plasma concentration curve, apparent volume of distribution and total body clearance) were similar for all four groups but there was considerable inter-subject variability. The correlations between these kinetic parameters and age, body weight and serum albumin were poor. The results suggest that any differences in the effects of corticosteroids in these inflammatory diseases are unlikely to be due to pharmacokinetic factors. The duration of steroid therapy and the reduction in patient mobility would appear to be more likely explanations for the reduction in bone mass observed in patients with RA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780140     DOI: 10.1007/bf02054250

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Analysis of prednisolone in plasma by high-performance liquid chromatography.

Authors:  J C Loo; A G Butterfield; J Moffatt; N Jordan
Journal:  J Chromatogr       Date:  1977-05-01

Review 3.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  M E Pickup
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

4.  Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.

Authors:  M Kozower; L Veatch; M M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

5.  Bone mass in corticosteroid treated patients with rheumatoid arthritis, asthma and polymyalgia rheumatica.

Authors:  D M Reid; J J Nicoll; N Brown; M A Smith; P Tothill; G Nuki
Journal:  Scott Med J       Date:  1985-01       Impact factor: 0.729

6.  Effectiveness of prednisolone during phenytoin therapy.

Authors:  L B Petereit; A W Meikle
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

7.  Steroid-induced fractures and bone loss in patients with asthma.

Authors:  A D Adinoff; J R Hollister
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

8.  Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment.

Authors:  D M Reid; N S Kennedy; M A Smith; P Tothill; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

9.  An evaluation of criteria for polymyalgia rheumatica.

Authors:  H A Bird; W Esselinckx; A S Dixon; A G Mowat; P H Wood
Journal:  Ann Rheum Dis       Date:  1979-10       Impact factor: 19.103

10.  The binding of prednisolone in human serum and to recrystallized human albumin in vitro.

Authors:  W H Steele; G M Hawksworth; H E Barber
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.